Alivus Life Sciences Limited
1,586words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
August 04, 2022 To, Dy.General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 To, The Manager - Listing, National Stock Exchange of Indi
7.1%
wth with Europe being soft due to supply chain issues. Generic API business saw a healthy growth of 7.1% YoY ex-covid products, whereas CDMO business witnessed an impact due to inventory rationalisation a
INR 4,899
es, and I am optimistic about continuing the growth momentum in coming quarters.” end. We Revenue INR 4,899 mn l YoY, -6.7% l QoQ, -4.7% t YoY 7.7% ' YoY -5.0% 3 • Revenue decreased by 6.7% YoY.
6.7%
about continuing the growth momentum in coming quarters.” end. We Revenue INR 4,899 mn l YoY, -6.7% l QoQ, -4.7% t YoY 7.7% ' YoY -5.0% 3 • Revenue decreased by 6.7% YoY. However, exclud
4.7%
the growth momentum in coming quarters.” end. We Revenue INR 4,899 mn l YoY, -6.7% l QoQ, -4.7% t YoY 7.7% ' YoY -5.0% 3 • Revenue decreased by 6.7% YoY. However, excluding COVID produc
7.7%
mentum in coming quarters.” end. We Revenue INR 4,899 mn l YoY, -6.7% l QoQ, -4.7% t YoY 7.7% ' YoY -5.0% 3 • Revenue decreased by 6.7% YoY. However, excluding COVID products, growth at
5.0%
g quarters.” end. We Revenue INR 4,899 mn l YoY, -6.7% l QoQ, -4.7% t YoY 7.7% ' YoY -5.0% 3 • Revenue decreased by 6.7% YoY. However, excluding COVID products, growth at 6.5% YoY. • G
6.5%
' YoY -5.0% 3 • Revenue decreased by 6.7% YoY. However, excluding COVID products, growth at 6.5% YoY. • Gross margin improved to 53.3% driven by booking of PLI scheme incentive. Gross Margins e
53.3%
by 6.7% YoY. However, excluding COVID products, growth at 6.5% YoY. • Gross margin improved to 53.3% driven by booking of PLI scheme incentive. Gross Margins excluding PLI scheme incentive were sta
52.0%
n by booking of PLI scheme incentive. Gross Margins excluding PLI scheme incentive were stable at 52.0%. • • Improvement in EBITDA margin by 60bps YoY and 320bps QoQ Emerging market grew by 24% on Y
60bps
rgins excluding PLI scheme incentive were stable at 52.0%. • • Improvement in EBITDA margin by 60bps YoY and 320bps QoQ Emerging market grew by 24% on YoY basis ex-covid products • R&D expenditure
320bps
g PLI scheme incentive were stable at 52.0%. • • Improvement in EBITDA margin by 60bps YoY and 320bps QoQ Emerging market grew by 24% on YoY basis ex-covid products • R&D expenditure at 3.1% during
Advertisement